TLX Valuation

Telix Pharmaceuticals Ltd

Add to Watchlist

Advanced Chart

14.200

+0.31(2.232%)1D

Overview
Forecast
Valuation
Earnings

TLX Relative Valuation

TLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TLX is overvalued; if below, it's undervalued.

Historical Valuation

Telix Pharmaceuticals Ltd (TLX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 24.13 is considered Undervalued compared with the five-year average of 65.90. The fair price of Telix Pharmaceuticals Ltd (TLX) is between 23.37 to 44.21 according to relative valuation methord. Compared to the current price of 14.20 USD , Telix Pharmaceuticals Ltd is Undervalued By 39.23%.

Relative Value

Fair Zone

23.37-44.21

Current Price：14.20

39.23%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

12.40

P/B

Median3y

16.23

Median5y

16.23

0.20

FCF Yield

Median3y

0.18

Median5y

0.18

Competitors Valuation Multiple

The average P/S ratio for TLX's competitors is 8.56, providing a benchmark for relative valuation. Telix Pharmaceuticals Ltd Corp (TLX) exhibits a P/S ratio of 5.95, which is -30.54% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TLX.O

Telix Pharmaceuticals Ltd

5.95

Average P/S: 8.56

9.61B